

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Special Issue: Annals *Reports* LETTER TO THE EDITOR

Antenatal multiple micronutrient supplementation: call to action for change in recommendation

Megan W. Bourassa,¹ Saskia J.M. Osendarp,² Seth Adu-Afarwuah,⁴ Saima Ahmed,¹ Clayton Ajello,⁵ Gilles Bergeron,¹ Robert Black,⁶ Parul Christian,^{6,7} Simon Cousens,⁸ Saskia de Pee,^{3,9,10} Kathryn G. Dewey,¹¹ Shams El Arifeen,¹² Reina Engle-Stone,¹¹ Alison Fleet,¹³ Alison D. Gernand,¹⁴ John Hoddinott,¹⁵ Rolf Klemm,^{5,16} Klaus Kraemer,¹⁷ Roland Kupka,¹⁸ Erin McLean,^a Sophie E. Moore,¹⁹ Lynnette M. Neufeld,²⁰ Lars-Åke Persson,²¹ Kathleen M. Rasmussen,¹⁵ Anuraj H. Shankar,^{23,25} Emily Smith,^{22,26} Christopher R. Sudfeld,²² Emorn Udomkesmalee,²⁴ and Stephen A. Vosti¹¹

¹The New York Academy of Sciences, New York, New York, ²Micronutrient Forum, Washington, D.C. ³Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands. ⁴Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana. ⁵The Vitamin Angels Alliance, Inc., Santa Barbara, California. ⁶Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. ⁷Bill & Melinda Gates Foundation, Seattle, Washington. ⁸London School of Hygiene and Tropical Medicine, London, United Kingdom. ⁹UN World Food Programme, Rome, Italy. ¹⁰Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts. ¹¹Department of Agricultural and Resource Economics, University of California, Davis, Davis, California. ¹²International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh. ¹³UNICEF, Copenhagen, Denmark. ¹⁴The Pennsylvania State University, University Park, Pennsylvania. ¹⁵Division of Nutritional Sciences, Cornell University, Ithaca, New York. ¹⁶Helen Keller International, Baltimore, Maryland. ¹⁷Sight and Life Foundation, Basel, Switzerland. ¹⁸UNICEF, New York, New York. ¹⁹Department of Women and Children's Health, King's College London, London, United Kingdom.²⁰Global Alliance for Improved Nutrition GAIN, Geneva, Switzerland. ²¹London School of Hygiene and Tropical Medicine, Addis Ababa, Ethiopia. ²²Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ²³Summit Institute of Development, Mataram, Indonesia. ²⁴Institute of Nutrition, Mahidol University, Nakhon Pathom, Thailand. ²⁵Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom. ²⁶Departments of Global Health, and Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, D.C.

Address for correspondence: Megan W. Bourassa, The New York Academy of Sciences, 250 Greenwich Street, 40th Floor, New York, NY 10007–2157. mbourassa@nyas.org

We appreciate the comments by Devakumar *et al.*¹ and agree that there are still some unanswered questions regarding the long-term impact of multiple micronutrient supplementation (MMS) during pregnancy. However, in their assessment, Devakumar and colleagues ignore the significant benefits shown in the individual patient data (IPD) meta-analysis, which strongly influenced our task force's conclusions. Rather, their comments focus only on the birth size data from the *Cochrane* reviews.^{2,3} In the IPD meta-analysis, which included data from nearly 113,000 pregnancies, the authors found that, in addition to reducing the risk of low birthweight, MMS significantly reduces the risk of preterm birth

(RR = 0.93 (0.87-0.98), random effects).² The *Cochrane* review also states that MMS "probably led to a slight reduction in preterm births" on the basis of data from 91,425 participants with moderate quality evidence (RR = 0.95 (0.90-1.01)).³

One of the greatest strengths of an IPD metaanalysis is the ability to include predefined subgroup analyses that are based on the individual data, rather than trial-level aggregate data. The meta-analysis in the *Cochrane* review only used the latter. In the IPD meta-analysis, the authors found that MMS (compared with iron and folic acid supplementation) significantly reduced neonatal mortality among female infants (RR = 0.85 (0.75–0.96)), and had similar significant effects on 6-month and infant mortality, with no effect among males, and reduced 6-month mortality (RR = 0.71 (0.60–0.86)) among all infants

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in

^aFormerly at UNICEF, New York, New York.

doi: 10.1111/nyas.14271

Ann. N.Y. Acad. Sci. xxxx (2019) 1–3 © 2019 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals, Inc. on behalf of New York Academy of Sciences

born to anemic mothers.² The subgroup analyses also showed that the benefit of MMS with regard to reducing the risk of preterm birth (RR = 0.84 (0.78-0.91)) was greater among infants born to underweight mothers than among those born to women who were not underweight. The global prevalence estimates of underweight (>200 million women of reproductive age) 4 and anemia (>528 million women of reproductive age)⁵ are very high, and prevalence rates are highest in low- and middleincome countries, where these MMS trials took place. Thus, in such settings, MMS is likely to benefit a substantial proportion of infants. The potential benefits of MMS for women who are depleted in nutrients other than iron and folate also merit further exploration.

In addition to the short-term benefits of MMS with regard to birth outcomes, the likely longer term consequences of reducing low birthweight and preterm birth should be considered. Low birthweight infants are at an increased risk of death not just during infancy but throughout life, and low birthweight is also associated with reduced lung capacity and immune function as well as an increase in certain cancers.⁶ Reducing low birthweight rates remains a World Health Assembly target, and interventions that can reduce the risk of low birthweight, such as MMS, should be encouraged.

More information would be useful regarding the long-term benefits or consequences of all prenatal interventions. For MMS, the evidence continues to accrue from long-term follow-up of trial participants. We note that the Devakumar et al. standard aggregated data meta-analysis includes mortality and anthropometric data for follow-up periods ranging from 6 months to 9 years after birth and combines studies that did and did not continue nutritional interventions after birth, making direct comparisons across studies difficult.⁷ Moreover, there is a risk of bias in the existing evidence from follow-up studies because of loss to follow up due to mortality. Valid and reliable cognitive assessments in very young children remain a challenge, which reduces the likelihood of detecting intervention group differences; a much wider array of assessments can be conducted among older children and adults. Recent results on adolescent cognition from a study in rural Western China are encouraging (and appear to have been overlooked by Devakumar et al. in their letter).8 In that

study, which included more than 2,100 14-year olds, the investigators found that children whose mothers received MMS during pregnancy had a dosedependent improvement in intellectual development. The findings of that study are similar to those of the follow-up study of school-age children in the Indonesian SUMMIT study at 9–12 years of age.⁹

On the basis of the evidence provided by the *Cochrane* review and the IPD meta-analysis, the task force is of the opinion that there is sufficient evidence to inform policy decisions now, without waiting for more evidence on long-term outcomes. We agree with Devakumar *et al.* that improving health outcomes through nutrition interventions requires a life-course approach. MMS is just one intervention during one phase of the life course, and pregnant women in food-insecure situations may need improved macro- as well as micronutrient intake. That said, in populations at risk, MMS during pregnancy can allow infants to begin life with a significant advantage.

Acknowledgment

Open access to this article was sponsored by the Bill & Melinda Gates Foundation.

Competing interests

The authors declare no competing interests.

References

- Devakumar, D., D. Osrin, H.S. Sachdev & A. Prost. 2019. Antenatal multiple micronutrient supplementation: where are the long-term benefits? *Ann. N.Y. Acad. Sci.* https://doi. org/10.1111/nyas.14272.
- 2. Smith, E.R., A.H. Shankar, L.S.-F. Wu, *et al.* 2017. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. *Lancet Glob. Health* **5:** e1090–e1100.
- Keats, E.C., B.A. Haider, E. Tam, et al. 2019. Multiplemicronutrient supplementation for women during pregnancy. Cochrane Database Syst. Rev. 3: CD004905.
- 4. Bentham, J., M. Di Cesare, V. Bilano, *et al.* 2017. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128-9 million children, adolescents, and adults. *Lancet* **390:** 2627–2642.
- 5. World Health Organization. 2015. The global prevalence of anaemia in 2011. WHO Report. Geneva: WHO.
- Victora, C.G., L. Adair, C. Fall, *et al.* 2008. Maternal and child undernutrition: consequences for adult health and human capital. *Lancet* 371: 340–357.

- Devakumar, D., C.H.D. Fall, H.S. Sachdev, *et al.* 2016. Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis. *BMC Med.* 14: 90.
- Zhu, Z., Y. Cheng, L. Zeng, *et al.* 2018. Association of antenatal micronutrient supplementation with adolescent intellectual development in rural western China 14-year follow-

up from a randomized clinical trial. JAMA Pediatr. 172: 832-841.

 Prado, E.L., S.K. Sebayang, M. Apriatni, *et al.* 2017. Maternal multiple micronutrient supplementation and other biomedical and socioenvironmental influences on children's cognition at age 9–12 years in Indonesia: follow-up of the SUMMIT randomised trial. *Lancet Glob. Health* 5: e217–e228.